Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin. [1]
-
^ Hutchinson, Michael (2007).
"Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268.
doi:
10.2147/tcrm.2007.3.2.259.
ISSN
1176-6336.
{{ cite journal}}: CS1 maint: unflagged free DOI ( link)
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin. [1]
-
^ Hutchinson, Michael (2007).
"Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268.
doi:
10.2147/tcrm.2007.3.2.259.
ISSN
1176-6336.
{{ cite journal}}: CS1 maint: unflagged free DOI ( link)